In 2025, Ascendis Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Ascendis Pharma has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2025 | 2024 |
|---|---|---|
Total Scope 1 | 69a | 62a |
Total Scope 2 | ||
Market-Based | 652a | 547a |
Location-Based | 1,054a | 862a |
Total Scope 3 | N/A | N/A |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0.0815a | 0.1377a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Ascendis Pharma amounted to 1,123 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Ascendis Pharma increased by 21.54%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Ascendis Pharma were 69 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2024), Ascendis Pharma's Scope 1 emissions increased by 11.29%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2025, Ascendis Pharma reported Scope 2 greenhouse gas (GHG) emissions of 652 tCO₂e using the market-based method and 1,054 tCO₂e using the location-based method.a
Compared to the previous year (2024), Ascendis Pharma's Scope 2 emissions (Location-Based) rose by 22.27% in 2025, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2025, Ascendis Pharma reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, Ascendis Pharma reported Scope 1 greenhouse gas (GHG) emissions of 69 tCO₂e and total revenues of USD 847 millions. This translates into an emissions intensity of 0.08 tCO₂e per millions USD.a
In 2025, Ascendis Pharma reported a Scope 1 emissions intensity of 0.08 tCO₂e per millions USD. Compared to the peer group median of 2.77, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Ascendis Pharma ranked 5 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Ascendis Pharma among the top performers, with one of the lowest emissions intensities relative to peers.a